FMR1 and fragile X syndrome: While preclinical testing of targeted treatment strategies aimed at compensating for the loss of FMRP has been successful in mouse models of FXS (reviewed in [37]), many of the clinical trials based on these studies were unsuccessful (see [38] for a recent review).